Media Articles Related to Guanfacine
Yoga Improves Quality of Life in Pulmonary Hypertension
Source: Medscape Critical Care Headlines [2016.04.29]
Adults with pulmonary arterial hypertension could derive some relief from yoga, results from a preliminary study suggest. The 12-week program eased anxiety and depression, among other measures.
Medscape Medical News
RA: Hypertension, High LDL Often Missed or Undertreated
Source: Medscape Rheumatology Headlines [2016.04.25]
Patients with rheumatoid arthritis are likely to need more intensive monitoring and treatment of cardiovascular risk factors, but often receive less.
Medscape Medical News
Healthy diet could lower hypertension risk for women with gestational diabetes
Source: Diabetes News From Medical News Today [2016.04.19]
Researchers have found that the long-term risk of high blood pressure that is caused by pregnancy-related diabetes could be reduced by following a healthy diet.
Source: MedicineNet Fainting Specialty [2016.03.30]
Title: Pulmonary Hypertension
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 3/30/2016 12:00:00 AM
High Blood Pressure (Hypertension) Quiz: Test Your Medical IQ
Source: MedicineNet Nosebleed Specialty [2016.01.05]
Title: High Blood Pressure (Hypertension) Quiz: Test Your Medical IQ
Category: MedicineNet Quiz
Created: 2/9/2011 12:56:00 PM
Last Editorial Review: 1/5/2016 2:12:26 PM
Published Studies Related to Guanfacine
Efficacy of guanfacine extended release assessed during the morning, afternoon,
and evening using a modified Conners' Parent Rating Scale-revised: Short Form. 
attention-deficit/hyperactivity disorder (ADHD)... CONCLUSIONS: These results provide further support for the demonstrated efficacy
Randomized, double-blind trial of guanfacine extended release in children with
attention-deficit/hyperactivity disorder: morning or evening administration. 
CONCLUSIONS: GXR administered either in the morning or evening was associated
Naltrexone with or without guanfacine for preventing relapse to opiate addiction
in St.-Petersburg, Russia. 
induced craving and have reduced opiate relapse in small clinical trials... CONCLUSIONS: Adding guanfacine to naltrexone did not improve treatment retention
Guanfacine extended-release: in attention deficit hyperactivity disorder. [2010.09.10]
Guanfacine, an alpha(2A)-adrenoceptor agonist, is available in the US as an extended-release (ER) tablet for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents (aged 6-17 years). In two large, randomized, double-blind, placebo-controlled trials of 8 and 9 weeks' duration, guanfacine ER (1-4 mg once daily) was effective in reducing the symptoms of ADHD (hyperactivity, impulsivity and inattention) in children and adolescents...
Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. [2010.09.01]
CONCLUSIONS: In this population of children aged 6-12 years with ADHD and the presence of oppositional symptoms, significant reductions in CPRS-R:L oppositional subscale and ADHD-RS-IV total scores were observed with guanfacine XR treatment compared with placebo. Treatment with guanfacine XR at optimized doses was associated with mostly mild or moderate TEAEs. The findings of this study support the efficacy of guanfacine XR in the treatment of children with ADHD and the presence of oppositional symptoms. Clinical Trial Registration Number: NCT00367835.
Clinical Trials Related to Guanfacine
PK/PD Comparison of Guanfacine ER and IR [Active, not recruiting]
Evaluate whether a 4mg/day or 6/mg day dose of extended-release guanfacine produces
pharmacokinetic/dynamic (PK/PD) properties similar to 3mg/day immediate release guanfacine.
Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65). [Completed]
This is considered an investigator-initiated clinical research trial, which means that your
study doctor is researching a particular medication (in this case a medication that is
currently FDA- approved) for the treatment of AD/HD in individuals ages 6-17. The medication
is guanfacine hydrochloride.
The hypothesis is that this medication could be used in adults with Attention
Deficit/Hyperactivity Disorder who have not received satisfactory results with their current
stimulant ADHD medication. The study drug is investigational for use in adults.
Investigational means it has not been approved by the U. S. Food and Drug Administration
(FDA) for use in adults.
Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence [Completed]
The purpose of this study is to determine whether guanfacine represents a tolerable,
potentially effective pharmacotherapy option for cannabis dependence. Interested in seeing
whether guanfacine treatment reduces marijuana consumption, withdrawal symptoms, and craving
as compared to baseline.
Does Guanfacine Attenuate Stress-Induced Drinking? [Recruiting]
Evaluating the effect of guanfacine on alcohol consumption. The investigators hypothesize
that guanfacine versus placebo will decrease the number of drinks consumed during the 2-hour
self-administration period across stress and neutral/relaxing conditions.
Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH) [Recruiting]
Combination of guanfacine with opioid medication as a standard treatment for chronic pain.
Reports of Suspected Guanfacine Side Effects
Confusional State (3),
Coordination Abnormal (3),
Swelling Face (3),
Swollen Tongue (3),
Blood Pressure Decreased (3),
Complex Partial Seizures (3),
LIP Swelling (1), more >>